ADC Therapeutics reports Q3 adjsuted EPS (19c), consensus (36c)

Reports Q3 revenue $15.8M, consensus $16.79M. As of September 30 cash and cash equivalents were $234.7M, compared to $250.9M as of December 31, 2024.”The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas,” said Ameet Mallik, CEO of ADC Therapeutics (ADCT). “We look forward to multiple upcoming clinical catalysts expected across LOTIS-7, LOTIS-5, and the ongoing Phase 2 IITs, starting with LOTIS-7 before the end of this year and continuing with data readouts throughout 2026.”